Clinical trial
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in…
NCT00171210 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171210 |
|---|---|
| Title | An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload |
| Official title | An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Transfusional Iron Overload in β-thalassemia |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 506 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | May 30, 2011 |
| Countries | Argentina, Belgium, Brazil, Canada, France, Germany, Greece, Italy, Tunisia, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: